Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Revvity

Close the acquisition of BioLegend by the end of 2021

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
27 Jul 2021
Due
31 Dec 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions”
  • SourceRevvity Form 8-K press release, 2021-07-27
  • FilingSEC filing index
  • Deadline as statedby the end of the 2021 calendar year
  • Deadline used31 Dec 2021, the last day of the stated period
  • TypeTransaction
  • Permanent referenceKI-C-2021-RVTY-006368
    Cite as https://keptindex.org/c/KI-C-2021-RVTY-006368/ — this address never changes.

What we found

Evidence strength A What the grades mean

The 10-K for fiscal 2021 states BioLegend was completed in that year, which ended January 2, 2022. The exact closing date is not given.

  • A
    Revvity 10-K filed 2022-03-03 Regulatory filing · published 3 Mar 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 0351b6c24b5b
    “In fiscal year 2021, we completed the acquisition of BioLegend, Inc. ("BioLegend") and paid an aggregate purchase price of $5.7 billion” ✓ confirmed on the page
  • A
    Revvity 10-K filed 2022-03-03 Regulatory filing · published 3 Mar 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 0351b6c24b5b
    “PERKINELMER, INC.00000317911/21/2/20222021FYfalse” ✓ confirmed on the page

Market reaction: the shares moved +1.4% against the S&P 500 over the three sessions around the disclosure (2 Mar 2022 to 7 Mar 2022). What this measures

Checked 10 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Acquisition close
Indicative materiality
High rules
Action
Close
Deliverable
BioLegend acquisition closing
Language
Expected (“expects”, “plans”)
In the company’s control
Low
Specificity
High
Conditional
Yes: subject to regulatory approvals; other customary closing conditions
Depends on
Regulatory, Counterparty

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Revvity? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-RVTY-006368 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.